Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No antibody or cell therapy target in routine use for T-ALL.
Which high-risk children still need transplant once immunotherapy clears residual disease.
Nothing recorded yet.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Asparaginase toxicity and osteonecrosis in adolescents receiving the most intensive regimens.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
3-year OS 85% vs 68%; HR 0.
A milestone in how this cancer is treated.
Bortezomib did not significantly improve four-year event-free survival for the whole group (83.
A milestone in how this cancer is treated.
Nelarabine improved disease-free survival in T-cell acute lymphoblastic leukaemia, and Capizzi methotrexate outperformed high-dose methotrexate.